Skip to main
OPRX

OptimizeRx Corp (OPRX) Stock Forecast & Price Target

OptimizeRx Corp (OPRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

OptimizeRx Corp has demonstrated substantial financial growth, with contracted revenue increasing by 30% year-over-year and a notable revenue beat contributing to enhanced margins and earnings per share (EPS) performance. The company’s guidance for 2025 includes revenue growth expectations in the high teens to low twenties, reflecting strong visibility of over 85% for total revenue and at least 70% for the second half of 2025. Furthermore, projected EBITDA guidance surpasses consensus estimates, highlighting OptimizeRx's solid operational foundation and capability to maintain a revenue run-rate of approximately $150 million while keeping expenses stable.

Bears say

OptimizeRx Corp operates within the competitive healthcare technology market, yet it has recently experienced declining revenue growth, which raises concerns about its ability to maintain market share. Additionally, rising operational costs, coupled with increased research and development expenditures, may negatively impact profitability margins moving forward. Furthermore, the company faces regulatory challenges and potential disruptions in healthcare policy that could hinder its ability to execute its strategic initiatives effectively.

OptimizeRx Corp (OPRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OptimizeRx Corp (OPRX) Forecast

Analysts have given OptimizeRx Corp (OPRX) a Buy based on their latest research and market trends.

According to 5 analysts, OptimizeRx Corp (OPRX) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OptimizeRx Corp (OPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.